The much-anticipated decision in the case Wyeth v. Levine was announced today, in which the Court rejected, 6-3, the drug industry’s argument that FDA’s approval of a drug’s label should be a shield from liability under state tort law.
We’re as excited as those Legal Eagles over at Prescription Access Litigation, who blogged on the decision here.